caa a22 4500 465789846 CHVBK 20180323112020.0 cr unu---uuuuu 170327e19900301xx s 000 0 eng 10.1007/BF00171986 doi (NATIONALLICENCE)springer-10.1007/BF00171986 Phase II trial of fludarabine phosphate (F-ara-AMP) in patients with advanced head and neck cancer [Elektronische Daten] [A. Mittelman, S. Savona, C. Puccio, H. Chun, T. Ahmed, E. Feldman, P. Sullivan, P. Arnold, Z. Arlin] Summary: Thirteen patients with advanced head and neck cancer were entered into a phase II study of fludarabine phosphate. Fludarabine phosphate was given by continuous infusion for 5 days, at a starting dose of 20 mg/m2 per day for patients previously treated with one regimen and 25 mg/m2 per day for previously untreated patients; therapy was repeated every 3-4 weeks. Of the 13 patients, 3 had undergone one prior regimen and 10 patients were previously untreated by chemotherapy. No responses were observed. Myelosuppression was the most common toxicity observed. Four patients developed mild nausea, vomiting and seven developed bleeding stomatitis that resolved in one week. In addition, four patients developed headaches which resolved spontaneously. No renal, hepatic, or neurotoxicity was observed. Our study demonstrates that in previously treated and untreated patients, fludarabine phosphate given on this schedule has little activity in patients with advanced head and neck cancer. Kluwer Academic Publishers, 1990 fludarabine phosphate nationallicence fluro-Ara-Amp nationallicence head and neck cancer nationallicence Mittelman A. New York Medical College, 10595, Valhalla, NY, USA aut Savona S. New York Medical College, 10595, Valhalla, NY, USA aut Puccio C. New York Medical College, 10595, Valhalla, NY, USA aut Chun H. National Cancer Institute, 20892, Bethesda, MD, USA aut Ahmed T. New York Medical College, 10595, Valhalla, NY, USA aut Feldman E. New York Medical College, 10595, Valhalla, NY, USA aut Sullivan P. New York Medical College, 10595, Valhalla, NY, USA aut Arnold P. New York Medical College, 10595, Valhalla, NY, USA aut Arlin Z. New York Medical College, 10595, Valhalla, NY, USA aut Investigational New Drugs Kluwer Academic Publishers 8(1990-03-01), S65-S67 0167-6997 8<S65 1990 8 10637 https://doi.org/10.1007/BF00171986 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00171986 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Mittelman A. New York Medical College, 10595, Valhalla, NY, USA aut NATIONALLICENCE 700 1- Savona S. New York Medical College, 10595, Valhalla, NY, USA aut NATIONALLICENCE 700 1- Puccio C. New York Medical College, 10595, Valhalla, NY, USA aut NATIONALLICENCE 700 1- Chun H. National Cancer Institute, 20892, Bethesda, MD, USA aut NATIONALLICENCE 700 1- Ahmed T. New York Medical College, 10595, Valhalla, NY, USA aut NATIONALLICENCE 700 1- Feldman E. New York Medical College, 10595, Valhalla, NY, USA aut NATIONALLICENCE 700 1- Sullivan P. New York Medical College, 10595, Valhalla, NY, USA aut NATIONALLICENCE 700 1- Arnold P. New York Medical College, 10595, Valhalla, NY, USA aut NATIONALLICENCE 700 1- Arlin Z. New York Medical College, 10595, Valhalla, NY, USA aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8(1990-03-01), S65-S67 0167-6997 8<S65 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence SWISSBIB 464713889 BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer